Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sarita Barsainya"'
Autor:
Gilles Ndayisaba, Adoke Yeka, Kwaku Poku Asante, Martin P. Grobusch, Etienne Karita, Henry Mugerwa, Stephen Asiimwe, Abraham Oduro, Bakary Fofana, Seydou Doumbia, Jay Prakash Jain, Sarita Barsainya, Gerd A. Kullak-Ublick, Guoqin Su, Esther K. Schmitt, Katalin Csermak, Preetam Gandhi, David Hughes
Publikováno v:
Malaria Journal, Vol 20, Iss 1, Pp 1-10 (2021)
Abstract Background The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects in two trials: one
Externí odkaz:
https://doaj.org/article/890ef9801b434e61bb32253a0c40d2ec
Autor:
Adoke Yeka, Judith Straimer, Guoqin Su, Martin P. Grobusch, Kwaku Poku Asante, Vinay Kumar Venishetty, Sarfaraz Sayyed, Stephen Asiimwe, Gilles F. Ndayisaba, Sarita Barsainya, Abraham Oduro, Caroline Boulton, Henry Mugerwa, Esther K. Schmitt, Etienne Karita, Katalin Csermak Renner, Seydou Doumbia, P. Gandhi, Ivan Demin, Bakary Fofana
Publikováno v:
Clinical infectious diseases. Oxford University Press
Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976d24df7b3925eb85fe952adea3a862
https://pubmed.ncbi.nlm.nih.gov/34410358
https://pubmed.ncbi.nlm.nih.gov/34410358
Autor:
Ramachandra Sangana, Hemant Mittal, Sarita Barsainya, Aldo Hoermann, Parag Borde, Sachin Naik, Anup Vilas Thorat, Jie Zhang, Marie-Anne Valentin, Sampath Kalluri
Publikováno v:
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 16:102438
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor to treat type 2 diabetes mellitus, is available as immediate release (IR) tablets administered at 50 mg twice daily (BID). A 100 mg modified release (MR) formulation was developed for once dail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a666b4bf321e13b1c32dbfdc8e10260
https://doi.org/10.1016/j.dsx.2022.102438
https://doi.org/10.1016/j.dsx.2022.102438